XCURNasdaqPharmaceutical PreparationsFiscal year ends December 31
EXICURE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.03−0.09 (-8.04%)
Close on Oct 19, 2026
- Market cap
- $6.57M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -163.9% | -34.7% | -92.5% | |
| Return on assets | – | -22.9% | -34.0% | |
| Current ratio | 1.65 | 6.29 | 1.19 | |
| Debt to equity | 2.31 | 0.27 | – | |
| Net debt to EBITDA | 0.87× | 0.72× | – | |
| Interest coverage | -22.3× | -44.4× | -4233.0× | |
| Capex to revenue | 38.0% | 19.1% | – | |
| Diluted shares | 0M | 1M | 6M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Exicure generated $92.30M from operations and spent $979.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$92.30M
Used
$979.00K
Capital expenditure$979.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1940.2%
×Asset turnover0.04×
×Equity multiplier2.72×
=Return on equity, FY2024-197.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -1940.2% | 0.04× | 2.72× | -197.9% |
| FY2022 | -9.0% | 0.65× | 3.37× | -19.7% |
| FY2021 | 13271.6% | -0.01× | 2.27× | -176.3% |
| FY2020 | -148.5% | 0.15× | 1.52× | -34.7% |
| FY2019 | -2029.6% | 0.02× | 1.42× | -51.7% |
| FY2018 | -18994.1% | 0.00× | 1.41× | -109.5% |
| FY2017 | -113.3% | 0.39× | 2.21× | -98.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$4.95M
- Cash generatingOperating cash flow above zero-$8.56M
- Return on assets improvedROA up on the prior year-83.8% → -32.9%
- Earnings backed by cashOperating cash flow above net income-$8.56M vs -$4.95M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.45 → 1.19
- No dilutionShare count did not rise2M → 6M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.04 → 0.00